|
contents | business | |||||||||
| Jacobs receives contract for biotechnology project in Denmark Jacobs Engineering Group Inc. announced that they received a contract from Biogen Idec to provide engineering, procurement, validation, and site support services for the first cell culture manufacturing facility at the greenfield biotechnology plant in Hillerod, Denmark. The manufacturing facility is expected to produce TYSABRI (natalizumab), which is used in the treatment of multiple sclerosis. Officials did not disclose the contract details, but noted that the plant is scheduled to be completed in 2009. Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. The company creates new standards of care in therapeutic areas with high unmet medical needs and has significant products serving patients in more than 90 countries. This will be their first manufacturing facility in Europe. Jacobs performed conceptual design for the facility and will execute this new scope of work from their office in Reading, England. write your comments about the article :: © 2007 Construction News :: home page |